FINANCIAL NEWS

Jordan’s Hikma faces lower full-year revenue

11 Nov 2016

(MENAFN) Hikma Pharmaceuticals Plc reduced its full-year revenue predictions for its generics business, due to slower ramp-up in the unit.Moreover, the firm bought U.S generic drugs business this year, proclaimed that its now predict full-year revenue from the business to reach USD600mn.Accordingly, it also said that it predicted full-year core operating profit from its generics unit to be hurt by a delay in approval of new products.In addition, the firm predicts full-year revenue to grow by 35 percent to almost USD2bn in constant currency.

More News

This website uses cookies to ensure you get the best experience and by clicking “I Accept” below, you consent to the use of cookies. Learn more